Mp51-20 Clinicopathologic Risk Factors and Survival Outcomes for Metastatic Chromophobe Renal Cell Carcinoma

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging/Surveillance II (MP51)1 May 2024MP51-20 CLINICOPATHOLOGIC RISK FACTORS AND SURVIVAL OUTCOMES FOR METASTATIC CHROMOPHOBE RENAL CELL CARCINOMA Danielle Wang, Shengxuan Wang, and Heinric Williams Danielle WangDanielle Wang , Shengxuan WangShengxuan Wang , and Heinric WilliamsHeinric Williams View All Author Informationhttps://doi.org/10.1097/01.JU.0001009492.49624.4b.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Chromophobe renal cell carcinoma (chRCC) often carries a good prognosis unless it becomes metastatic. Using the American College of Surgeons National Cancer Database (NCDB), we evaluated the associated risk factors for metastatic chRCC and survival outcomes. METHODS: The NCDB was queried from 2004 to 2020 for all patients with chRCC. Clinicopathological factors of age, gender, ethnicity, synchronous metastatic status and sites, clinical/pathological stage, treatment type, co-morbidities, and follow-up were extracted. Numerical variables are summarized using median and interquartile range (IQR). Categorical variables are summarized using frequency and percentages. Univariate and multivariate logistic regressions were developed to identify the factors associated with metastases and overall survival. Survival was estimated using Kaplan-Meier method. Cox proportional-hazards regression model was used to identify factors associated with survival. Statistical analysis was conducted using SAS®. Results were considered statistically significant if p value was ≤0.05. RESULTS: Of 30,030 patients with chRCC, those with clinical T0 or Tx disease, unknown metastatic status, unknown tumor size, or those with missing data were excluded, resulting in a final population of 25,564 patients. The synchronous metastatic rate was 1.4% (n=376). Increased age (Odds ratio (OR) 1.03, 95% confidence interval (CI) 1.02-1.04, p10 cm (OR 11.98, 95% CI 1.67-86.19, p<0.0001) were independently associated with synchronous metastases on multivariate analyses. While the most common reported metastatic sites included bone (n=129), lung (n=103) and other (n=234), there was no difference in 5-year survival stratified by site (p=0.238). Factors associated with 5-year survival among metastatic patients included treatment (p<0.001) and clinical T stage (p<0.001). Among the treatment options evaluated, with no treatment as the referent, 5-year survival was best for partial nephrectomy (HR 0.303, 95% CI 0.14-0.68, p<0.001). The 5-year survival (95% CI) for those with chRCC metastases who underwent partial nephrectomy was 42.7% (16.1-67.2). CONCLUSIONS: While metastases are relatively rare in patients with chRCC, prognosis was poor irrespective of site of metastasis. Among those undergoing primary partial nephrectomy, total nephrectomy or no treatment, partial nephrectomy patients had the best 5-year survival. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e850 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Danielle Wang More articles by this author Shengxuan Wang More articles by this author Heinric Williams More articles by this author Expand All Advertisement PDF downloadLoading ...